← BIO-RAD LABORATORIES, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2.1b | $2.2b |
$2.3b
+5.98%
|
$2.3b
+0.97%
|
$2.5b
+10.12%
|
$2.9b
+14.81%
|
$2.8b
-4.12%
|
$2.7b
-4.67%
|
$2.6b
-3.92%
|
$2.6b
+0.65%
|
$2.6b
+0.24%
|
|
| Revenue from Contract with Customer, Including Assessed Tax | $2.1b | $2.2b | $2.3b | $2.3b | $2.5b | $2.9b | $2.8b | $2.7b | $2.6b | $2.6b | — | |
| Cost of Revenue | $930.1m |
$972.8m
+4.59%
|
$1.1b
+9.61%
|
$1.1b
-1.09%
|
$1.1b
+5.04%
|
$1.3b
+15.71%
|
$1.2b
-3.66%
|
$1.2b
+0.76%
|
$1.2b
-4.56%
|
$1.2b
+4.69%
|
$1.2b
+0.18%
|
|
| Gross Profit | $1.1b |
$1.2b
+4.33%
|
$1.2b
+3.01%
|
$1.3b
+2.77%
|
$1.4b
+14.39%
|
$1.6b
+14.11%
|
$1.6b
-4.47%
|
$1.4b
-8.96%
|
$1.4b
-3.37%
|
$1.3b
-2.83%
|
$1.3b
+0.29%
|
|
| Research and Development Expense | $205.9m | $250.3m | $199.2m | $202.7m | $226.6m | $271.7m | $256.9m | $247.4m | $295.9m | $275.6m | $265.7m | |
| Selling, General and Administrative Expense | $816.7m | $808.9m | $834.8m | $824.6m | $800.3m | $879.6m | $827.8m | $841.7m | $814.0m | $844.3m | $852.2m | |
| Amortization of Intangible Assets | $35.2m | $30.8m | $28.3m | $23.5m | $27.5m | $28.4m | $24.9m | $23.8m | $21.2m | $23.8m | — | |
| Operating Income (Loss) | $53.2m |
$116.7m
+119.29%
|
($103.3m)
-188.59%
|
$229.7m
+322.24%
|
$411.0m
+78.94%
|
$489.4m
+19.10%
|
$482.6m
-1.39%
|
$337.8m
-30.01%
|
$269.0m
-20.37%
|
$47.2m
-82.45%
|
$224.5m
+375.64%
|
|
| Interest Expense | $21.9m | $21.9m | $24.0m | $23.4m | $21.9m | $1.6m | $38.1m | $49.4m | $48.9m | $49.0m | $48.8m | |
| Debt and Equity Securities, Gain (Loss) | — | — | $1.6m | $1.5m | $700k | — | — | — | — | — | — | |
| Debt and Equity Securities, Unrealized Gain (Loss) | — | — | — | — | — | $4.9b | ($5.2b) | ($1.3b) | ($2.7b) | $900.4m | — | |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | — | $100.6m | $6.8m | ($12.5m) | ($12.4m) | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($4.5m) | ($9.1m) | ($2.9m) | ($2.2m) | ($1.8m) | ($2.8m) | $205k | $7.3m | $3.9m | $6.6m | — | |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | ($19.9m) | $9.9m | ($20.7m) | $43.5m | — | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | ($1.2m) | $0 | ($900k) | ($1.3m) | $1.2m | ($200k) | ($1.3m) | ($2.2m) | ($1.3m) | — | |
| Other Nonoperating Income (Expense) | $14.8m | $12.2m | $36.6m | $26.1m | $24.5m | $26.8m | $44.6m | $106.4m | $90.3m | $90.3m | — | |
| Nonoperating Income (Expense) | $0 | — | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($38.5m) | $72.8m | $363.4m | $1.0b | $2.3b | $2.9b | ($2.4b) | ($31.0m) | ($1.1b) | $801.4m | $350.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | $2.3b | $4.9b | $5.4b | ($4.7b) | ($850.1m) | ($2.3b) | $995.5m | $350.4m | |
| Current Income Tax Expense (Benefit) | $49.5m | $42.1m | $41.5m | $40.9m | $104.2m | $114.2m | $157.0m | $103.2m | $123.5m | $63.0m | $128.0m | |
| Income Tax Expense (Benefit) | $13.4m | ($24.4m) | $147.0m | $502.4m | $1.1b | $1.2b | ($1.1b) | ($212.8m) | ($498.3m) | $235.6m | $128.0m | |
| Net Income (Loss) Attributable to Parent | $28.1m |
$122.2m
+334.66%
|
$365.6m
+199.07%
|
$1.8b
+381.02%
|
$3.8b
+116.43%
|
$4.2b
+11.55%
|
($3.6b)
-185.44%
|
($637.3m)
+82.43%
|
($1.8b)
-189.37%
|
$759.9m
+141.20%
|
$222.4m
-70.73%
|
|
| Earnings Per Share, Basic | $0.96 | $4.12 | $12.25 | $58.93 | $127.86 | $142.33 | ($121.79) | ($21.82) | ($65.36) | $27.87 | $8.23 | |
| Earnings Per Share, Diluted | $0.95 | $4.07 | $12.10 | $58.27 | $126.20 | $140.56 | ($121.79) | ($21.82) | ($65.36) | $27.85 | $8.21 | |
| Weighted Average Number of Shares Outstanding, Basic | 29.4m | 29.7m | 29.8m | 29.8m | 29.8m | 29.8m | 29.8m | 29.2m | 28.2m | 27.3m | 26.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | 29.6m | 30.0m | 30.2m | 30.2m | 30.2m | 30.2m | 29.8m | 29.2m | 28.2m | 27.3m | 26.9m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | $13.5m | $11.5m | $282.0m | $0 | $0 | $0 | $0 | $0 | — | — | $172.8m | |
| Realized Investment Gains (Losses) | $800k | $100k | $1.6m | $1.5m | $1.0m | $8.0m | $2.3m | $700k | $6.7m | $1.0m | — | |
| Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component | — | — | — | — | — | — | ($300k) | ($400k) | ($500k) | ($600k) | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.